Ratings Bristol-Myers Squibb Company Berne S.E.

Equities

BMY

US1101221083

End-of-day quote Berne S.E. Other stock markets 23:00:00 20/06/2024 BST			5-day change	1st Jan Change
54.24 ^CHF	0.00%		0.00%	0.00%

06-26	2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	MT
06-26	Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The company is one of the best yield companies with high dividend expectations.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The group shows a rather high level of debt in proportion to its EBITDA.
The company appears highly valued given the size of its balance sheet.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
BRISTOL-MYERS SQUIBB COMPANY	0.00%	85.52B	-
ELI LILLY AND COMPANY	+54.61%	815B	C+
NOVO NORDISK A/S	+44.25%	654B	B
JOHNSON & JOHNSON	-6.33%	354B	C+
MERCK & CO., INC.	+20.62%	337B	B-
ABBVIE INC.	+10.44%	302B	C+
ASTRAZENECA PLC	+18.45%	247B	B+
ROCHE HOLDING AG	+2.09%	229B	A+
NOVARTIS AG	+13.03%	219B	B-
AMGEN INC.	+8.61%	171B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes